CTXR stock

Is Citius Pharmaceuticals Inc (CTXR) overvalued? · $13.4M cap

Citius Pharmaceuticals Inc (CTXR) is a biotechnology company listed on US.

This page asks whether Citius Pharmaceuticals Inc (CTXR) looks expensive on cached numbers — not a short thesis.

No cached income statement for CTXR, so there is no earnings base to call rich or cheap.

CTXR currently screens at market cap $13.4M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.

If the next CTXR 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.

Not investment advice. Use the CTXR stock page for the full model, not this heading.

Not investment advice.

Full CTXR analysis